Monday, May 16, 2016

BRIEF-Corbus Pharmaceuticals Holdings Q1 loss per share $0.08

* Plans to initiate a clinical study in systemic lupus

erythematosus ( SLE ) in Q1 of 2017

Source text for Eikon: (http://1.usa.gov/1NvvLgy)

Further company coverage:

(Bengaluru Newsroom: +1 646 223 8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)